AlzeCure Hunts For Small Molecules In Its Alzheimer’s Quest

Swedish Biotech Is Developing Broad CNS portfolio

 
• By Sten Stovall

Emerging Company Profile: Swedish biotech AlzeCure is developing a portfolio of small-molecule drug candidates for diseases affecting the central nervous system, including Alzheimer’s disease and pain.

Emerging Company Profile: AlzeCure
CEO says potential small-molecule therapies could offer big advantages over biologics • Source: Alamy

More from Clinical Trials

More from R&D